Verus Sues AstraZeneca For $1.28B Over Deals To Develop Pediatric Asthma Drug

Verus claims that it is being “destroyed” by AstraZeneca’s move to terminate a high-value pediatric asthma deal.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet